PathAI
AI-powered pathology platform to improve patient outcomes through precision diagnostics
Enterprise·Technical·Powered by PathAI (proprietary)·API available
Key strengths
FDA-cleared and CE-IVDR marked digital pathology platform (AISight® Dx)First AI tool to receive FDA qualification for MASH clinical trials (AIM-MASH)Proprietary network of 450+ board-certified pathologists contributing 32.5M+ annotationsTrusted by 90% of the top 15 BioPharma companiesComprehensive AI algorithm suite covering tumor detection, biomarker quantification, and dermatology
Enterprise pricing
Boston, USA
Founded 2016
No ratings yet
No content available for this audience yet.